Get the Stockscreener App
3.10
0.96%
-0.03
Pre-market:
3.25
0.15
+4.84%
Protara Therapeutics Inc stock is traded at $3.10, with a volume of 145.95K.
It is down -0.96% in the last 24 hours and up +1.64% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$3.13
Open:
$3.13
24h Volume:
145.95K
Relative Volume:
0.46
Market Cap:
$119.60M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.0993
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-1.90%
1M Performance:
+1.64%
6M Performance:
-24.39%
1Y Performance:
+63.16%
1-Day Range:
$3.01
$3.138
1-Week Range:
$3.01
$3.21
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.10 | 120.76M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Published on: 2025-08-12 02:18:08 - Newser
Smart tools for monitoring Protara Therapeutics Inc.’s price actionFree Sector Based Breakout Stock Forecast - Newser
Is Protara Therapeutics Inc. in a bullish channelHigh Growth With Low Risk - mustnews.co.kr
Protara Therapeutics Reports Q2 2025 Financial Results - TipRanks
Using data filters to optimize entry into Protara Therapeutics Inc.Growth Projection Summary for Long-Term Investors - Newser
Applying big data sentiment scoring on Protara Therapeutics Inc.Free Growth Focused Entry Plan Suggestions - Newser
Protara Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Protara Therapeutics reports Q2 EPS (35c), consensus (38c) - TipRanks
Protara’s Losses Grew But Wall Street’s Still On Board - Finimize
Protara Beats Q2 Loss Estimates - The Motley Fool
Protara Therapeutics Q2 2025 Financial Results and Business Update - TradingView
Protara Therapeutics' Q2 net loss widens - MarketScreener
Protara Therapeutics, Inc. SEC 10-Q Report - TradingView
Protara (TARA) Announces Q2 2025 Results; Press Release Furnished | TARA SEC FilingForm 8-K - Stock Titan
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Protara Therapeutics Reveals Strong $146M Cash Position, Multiple Clinical Milestones Coming in Next 6 Months - Stock Titan
Using RSI to spot recovery in Protara Therapeutics Inc.Equity Portfolio Outlook and Performance Summary - Newser
Backtesting results for Protara Therapeutics Inc. trading strategiesFast Return Equity Forecast With Logic - Newser
News impact scoring models applied to Protara Therapeutics Inc.Free Top Gaining Picks With Entry Signals - Newser
Tick level data insight on Protara Therapeutics Inc. volatilityFree Weekly Hot Picks With Buy Confidence - Newser
Understanding Protara Therapeutics Inc.’s price movementMomentum Detection with Entry Optimization - Newser
Published on: 2025-08-10 02:01:28 - Newser
How Protara Therapeutics Inc. stock performs during market volatilityFree Pattern Alert With ROI Driven Strategy - Newser
Does Protara Therapeutics Inc. fit your quant trading modelFree Entry Alert With Low Drawdown Strategy - Newser
Protara Therapeutics Inc. stock volume spike explainedPattern Breakout Tracker with Screener Tools - Newser
Combining price and volume data for Protara Therapeutics Inc.Neural Network Based Equity Prediction System - Newser
What earnings revisions data tells us about Protara Therapeutics Inc.Free Trade Setups With AI Powered Filters - Newser
How to build a custom watchlist for Protara Therapeutics Inc.Short-Term AI-Based Stock Price Forecast - Newser
Why Protara Therapeutics Inc. stock attracts strong analyst attentionSmart Entry Signals for Active Traders - Newser
What analysts say about Protara Therapeutics Inc. stockCapitalize on momentum stocks before they peak - Jammu Links News
When is Protara Therapeutics Inc. stock expected to show significant growthTransform your portfolio with high-yield stocks - Jammu Links News
How does Protara Therapeutics Inc. compare to its industry peersOutstanding trading profits - Jammu Links News
Should I hold or sell Protara Therapeutics Inc. stock in 2025Capitalize on market momentum for big wins - Jammu Links News
What catalysts could drive Protara Therapeutics Inc. stock higher in 2025Free Consultation - Jammu Links News
What are Protara Therapeutics Inc. company’s key revenue driversMaximize portfolio growth with expert advice - Jammu Links News
What are analysts’ price targets for Protara Therapeutics Inc. in the next 12 monthsPhenomenal returns - Jammu Links News
What is Protara Therapeutics Inc. company’s growth strategyGet real-time alerts on top stocks - Jammu Links News
What institutional investors are buying Protara Therapeutics Inc. stockDouble or triple returns - Jammu Links News
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics Grants $45K Worth of Stock Options and RSUs to Strategic New Employees - Stock Titan
Protara Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):